Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates

Vaccine

Volumn 26, Issue 7, 2008, Pages 947-955

  Yan, Ming ^a   Roehrl, Michael H ^b   Basar, Emre ^a   Wang, Julia Y ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Anthrax; Protective antigen; Vaccine

Indexed keywords

ANTHRAX TOXIN; ANTHRAX VACCINE; BACTERIAL ANTIGEN; EPITOPE; IMMUNOGLOBULIN G; MUTANT PROTEIN; NEUTRALIZING ANTIBODY; PROTECTIVE ANTIGEN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; WILD TYPE;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; CELL LINE; FEMALE; MACROPHAGES; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; MUTATION; NEUTRALIZATION TESTS;

EID: 38649141825     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.11.087     Document Type: Article

References (34)

1. In: Joellenbeck L., Zwanziger L., Durch J., and Strom B. (Eds). The anthrax vaccine. Is it safe? Does it work? (2002), National Academy Press, Washington, DC
2. Smith H. Discovery of the anthrax toxin: the beginning of in vivo studies on pathogenic bacteria. Trends Microbiol 8 5 (2000) 199-200
3. Aulinger B.A., Roehrl M.H., Mekalanos J.J., Collier R.J., and Wang J.Y. Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines. Infect Immun 73 6 (2005) 3408-3414
4. Rhie G.E., Roehrl M.H., Mourez M., Collier R.J., Mekalanos J.J., and Wang J.Y. A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proc Natl Acad Sci USA 100 19 (2003) 10925-10930
5. Collier R.J., and Young J.A. Anthrax toxin. Annu Rev Cell Dev Biol 19 (2003) 45-70
6. Park J.M., Greten F.R., Li Z.W., and Karin M. Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science 297 5589 (2002) 2048-2051
7. Agrawal A., Lingappa J., Leppla S.H., Agrawal S., Jabbar A., Quinn C., et al. Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature 424 6946 (2003) 329-334
8. Leppla S.H. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci USA 79 10 (1982) 3162-3166
9. Bradley K.A., Mogridge J., Mourez M., Collier R.J., and Young J.A. Identification of the cellular receptor for anthrax toxin. Nature 414 6860 (2001) 225-229
10. Lacy D.B., Wigelsworth D.J., Melnyk R.A., Harrison S.C., and Collier R.J. Structure of heptameric protective antigen bound to an anthrax toxin receptor: a role for receptor in pH-dependent pore formation. Proc Natl Acad Sci USA 101 36 (2004) 13147-13151
11. Klimpel K.R., Molloy S.S., Thomas G., and Leppla S.H. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc Natl Acad Sci USA 89 21 (1992) 10277-10281
12. Beauregard K.E., Collier R.J., and Swanson J.A. Proteolytic activation of receptor-bound anthrax protective antigen on macrophages promotes its internalization. Cell Microbiol 2 3 (2000) 251-258
13. Mogridge J., Mourez M., and Collier R.J. Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin. J Bacteriol 183 6 (2001) 2111-2116
14. Mogridge J., Cunningham K., Lacy D.B., Mourez M., and Collier R.J. The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen. Proc Natl Acad Sci USA 99 10 (2002) 7045-7048
15. Sellman B.R., Mourez M., and Collier R.J. Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax. Science 292 5517 (2001) 695-697
16. Santelli E., Bankston L.A., Leppla S.H., and Liddington R.C. Crystal structure of a complex between anthrax toxin and its host cell receptor. Nature 430 7002 (2004) 905-908
17. Scobie H.M., Wigelsworth D.J., Marlett J.M., Thomas D., Rainey G.J., Lacy D.B., et al. Anthrax toxin receptor 2-dependent lethal toxin killing in vivo. PLoS Pathog 2 10 (2006) e111
18. Wei W., Lu Q., Chaudry G.J., Leppla S.H., and Cohen S.N. The LDL receptor-related protein LRP6 mediates internalization and lethality of anthrax toxin. Cell 124 6 (2006) 1141-1154
19. Wolfe J.T., Krantz B.A., Rainey G.J., Young J.A., and Collier R.J. Whole-cell voltage clamp measurements of anthrax toxin pore current. J Biol Chem 280 47 (2005) 39417-39422
20. Rainey G.J., Wigelsworth D.J., Ryan P.L., Scobie H.M., Collier R.J., and Young J.A. Receptor-specific requirements for anthrax toxin delivery into cells. Proc Natl Acad Sci USA 102 37 (2005) 13278-13283
21. Mourez M., Yan M., Lacy D.B., Dillon L., Bentsen L., Marpoe A., et al. Mapping dominant-negative mutations of anthrax protective antigen by scanning mutagenesis. Proc Natl Acad Sci USA 100 24 (2003) 13803-13808
22. Paccani S.R., Tonello F., Ghittoni R., Natale M., Muraro L., D'Elios M.M., et al. Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling. J Exp Med 201 3 (2005) 325-331
23. Comer J.E., Chopra A.K., Peterson J.W., and Konig R. Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo. Infect Immun 73 12 (2005) 8275-8281
24. Fang H., Xu L., Chen T.Y., Cyr J.M., and Frucht D.M. Anthrax lethal toxin has direct and potent inhibitory effects on B cell proliferation and immunoglobulin production. J Immunol 176 10 (2006) 6155-6161
25. Bryant P., and Ploegh H. Class II MHC peptide loading by the professionals. Curr Opin Immunol 16 1 (2004) 96-102
26. Abrami L., Lindsay M., Parton R.G., Leppla S.H., and van der Goot F.G. Membrane insertion of anthrax protective antigen and cytoplasmic delivery of lethal factor occur at different stages of the endocytic pathway. J Cell Biol 166 5 (2004) 645-651
27. Wang J.Y., and Roehrl M.H. Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin. Med Immunol 4 1 (2005) 4
28. Chen K.H., Liu S., Bankston L.A., Liddington R.C., and Leppla S.H. Selection of anthrax toxin protective antigen variants that discriminate between the cellular receptors TEM8 and CMG2 and achieve targeting of tumor cells. J Biol Chem (2007)
29. Petosa C., Collier R.J., Klimpel K.R., Leppla S.H., and Liddington R.C. Crystal structure of the anthrax toxin protective antigen. Nature 385 6619 (1997) 833-838
30. Rosovitz M.J., Schuck P., Varughese M., Chopra A.P., Mehra V., Singh Y., et al. Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J Biol Chem 278 33 (2003) 30936-30944
31. Zhang J., Xu J., Li G., Dong D., Song X., Guo Q., et al. The 2beta2-2beta3 loop of anthrax protective antigen contains a dominant neutralizing epitope. Biochem Biophys Res Commun 341 4 (2006) 1164-1171
32. Gubbins M.J., Berry J.D., Corbett C.R., Mogridge J., Yuan X.Y., Schmidt L., et al. Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen. FEMS Immunol Med Microbiol 47 3 (2006) 436-443
33. Brossier F., Levy M., Landier A., Lafaye P., and Mock M. Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect Immun 72 11 (2004) 6313-6317
34. Little S.F., Novak J.M., Lowe J.R., Leppla S.H., Singh Y., Klimpel K.R., et al. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology 142 Pt 3 (1996) 707-715